How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature

Author:

Alan Ozkan1ORCID,Kuzhan Okan2,Koca Sinan3,Telli Tugba Akin1ORCID,Basoglu Tugba1,Ercelep Ozlem1,Filinte Deniz4,Sengul Yildiz5,Arikan Huseyin6,Kaya Serap1,Babacan Nalan Akgul1,Dane Faysal1,Yumuk Perran Fulden1

Affiliation:

1. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey

2. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Yeditep University, Istanbul, Turkey

3. Division of Medical Oncology, Umraniye Research and Training Hospital, Istanbul, Turkey

4. Department of Pathology, Faculty of Medicine, Marmara University, Istanbul, Turkey

5. Department of Radiology, Faculty of Medicine, Marmara University, Istanbul, Turkey

6. Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey

Abstract

IntroductionInflammatory myofibroblastic tumor is a rare disease which is typically seen in children and young adults. Approximately half of the inflammatory myofibroblastic tumors contain translocations that result in over-expression of anaplastic lymphoma kinase gene. Herein, we present two anaplastic lymphoma kinase-positive cases with long-term remission with crizotinib. We do not know how long these therapies need to be continued.Case reportsWe present two cases of inflammatory myofibroblastic tumor treated with anaplastic lymphoma kinase inhibitor therapies: an 8-year-old Turkish boy and a 21-year-old Caucasian man.Management and outcomeTwo cases, both with good tumor control under crizotinib, but one who progressed on drug holiday, responded again to the same drug, and had a very short period of response after restarting crizotinib.ConclusionA molecular-targeted drug (anaplastic lymphoma kinase inhibitor) was found to be extremely effective as selective therapy for inflammatory myofibroblastic tumor with anaplastic lymphoma kinase translocation. Here, we want to emphasize the continuation of this treatment after achieving a good response until progression or a major side effect.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3